FGFR3 and achondroplasia: For example, variant-level information is useful when considering the use of C-type natriuretic peptide (CNP) analogue to aid in growth of long bones, as individuals with achondroplasia and a confirmed molecular diagnosis of the FGFR3 NP_000133 0.1:Gly380Arg substitution have shown increased annualized growth velocity in clinical trials data [10].